Condition: Lung Neuroendocrine Neoplasm · GEP Neuroendocrine Tumor · Sponsor: National Cancer Institute, Naples
The aim of CABOTEM study is to demonstrate the safety and activity of the Cabozantinib and Temozolomide combination in Lung and GEP-NENs patients, progressing after a first line therapy, including target therapies (everolimus, sunitinib) and / or chemotherapy, in the approved setting.
This description comes directly from the study's public registry record.
Salvatore Tafuto, MD · 081 5903 680 · s.tafuto@istitutotumori.na.it
Always discuss trial participation with your own doctor first.
| National Cancer Institute of Naples | Naples, Campania, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04893785